Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate) in patients with hormone-refractory disseminated prostate carcinoma

Scand J Urol Nephrol. 2000 Jun;34(3):188-93. doi: 10.1080/003655900750016571.


Material and methods: The present study investigates the safety and efficacy of 2590 MBq rhenium-186 (186Re) etidronate (i.e. twice the activity normally used) administered intravenously in 15 patients with disseminated prostatic carcinoma and bone pain.

Results: Pain relief was observed in 11 of 14 evaluable patients (79%), 4 of whom became completely free from pain. Five of the responding patients also noted an improvement in daily activity and two found it possible to reduce or discontinue morphine medication. Pain relief occurred within one week in four patients, and within two weeks in eight of the responding patients. The mean duration of pain relief after the first course of 186Re-etidronate was 6 weeks (range 4-10). The toxicity was mild (< or = grade 2), transient, and restricted to hematological toxicity.

Conclusions: 186Re-etidronate provided rapid pain-relief and had mild toxicity in most patients with disseminated hormone-refractory prostatic carcinoma, but doubling the activity did not markedly improve the efficacy.

Publication types

  • Evaluation Study

MeSH terms

  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / radiotherapy*
  • Bone Neoplasms / secondary*
  • Humans
  • Male
  • Pain Management*
  • Pain Measurement
  • Palliative Care*
  • Prostatic Neoplasms / pathology*
  • Radioisotopes / therapeutic use*
  • Radionuclide Imaging
  • Rhenium / therapeutic use*
  • Survival Analysis
  • Technetium Tc 99m Medronate
  • Treatment Outcome


  • Radioisotopes
  • Rhenium
  • Technetium Tc 99m Medronate